论文部分内容阅读
目前已经证实阿司匹林具有良好的心血管疾病二级预防作用,但目前预防普及率不到50%。因此阿司匹林还应该在患者人群中大力进行推广。1月17日,新英格兰杂志刊登了相关评述。ATC(Antithrombotic Trialists’ Collaboration)随机试验的荟萃分析结果显示,阿司匹林可分别减少主要冠脉事件和中风复发风险达20.0%和19.0%。此外,最近一项澳大利亚的研究显示,阿司匹林用于二级预防,不仅有健康转归获益,而且会有成本受益:预防的事件(非致命性心梗、中风、或任意原因的死亡)有48项,使用
Has now confirmed that aspirin has a good secondary prevention of cardiovascular disease, but the current prevention of penetration rate of less than 50%. Therefore, aspirin should also vigorously promote the patient population. January 17, New England magazine published relevant comments. A meta-analysis of randomized trials of ATC (Antithrombotic Trialists’ Collaboration) showed that aspirin reduced the risk of major coronary events and stroke recurrence by 20.0% and 19.0%, respectively. In addition, a recent Australian study showed that aspirin for secondary prevention not only benefits the health outcomes, but also benefits the cost: prevention events (non-fatal MI, stroke, or death from any cause) are 48, use